Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system

Cancer Lett. 2009 Oct 18;284(1):37-46. doi: 10.1016/j.canlet.2009.04.006. Epub 2009 May 12.

Abstract

Translation initiation commences with the binding of eIF-4F to the mRNA 5'-end cap. eIF-4F binds the cap structure via its eIF-4E subunit, which is the rate-limiting step for the initiation of translation. This pathway can be inhibited by 4E-binding proteins (4E-BPs). The present study investigated prolonged gemcitabine infusion in combination with reduced eIF-4E function on NSCLC cell viability in an in vitro bioreactor system. To assess attachment to the hollow fibers, cells with dominant active 4E-BP1 were first analyzed by scanning electron microscopy. Cells were treated with 0.5- or 2.5h (fixed dose rate) infusion (same total dose), simulating human plasma gemcitabine concentration-time profiles. An interaction was observed between fixed dose rate infusion gemcitabine and presence of dominant active 4E-BP1. We conclude that cap-dependent translation blockade and fixed dose rate infusion gemcitabine treatment results in a significant interaction affecting cell viability in vitro.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / pharmacology*
  • Bioreactors*
  • Carcinoma, Non-Small-Cell Lung
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Eukaryotic Initiation Factor-4E / genetics
  • Eukaryotic Initiation Factor-4E / metabolism*
  • Gemcitabine
  • Humans
  • Microscopy, Electron
  • Protein Biosynthesis
  • RNA, Messenger / metabolism*

Substances

  • Antimetabolites, Antineoplastic
  • Eukaryotic Initiation Factor-4E
  • RNA, Messenger
  • Deoxycytidine
  • Gemcitabine